Blog
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies
1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive c
…
5th Dec 2024
CB6 Biosimilar: Targeting SARS-CoV-2 with Cost-Effective Monoclonal Antibody Therapy
CB6, also known as Etesevimab, is a monoclonal antibody that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. It neutralizes the virus by preventing it from bind
…
4th Dec 2024
MHC Class I vs MHC Class II: Key Differences and Functions
Major Histocompatibility Complex (MHC) molecules are essential for immune recognition and response. They are specialized glycoproteins that present antigens to T cells, allowing the immun
…
22nd Nov 2024
SLAMF7: Activating Natural Killer Cells for Potent Anti-Cancer Responses
Introduction to SLAMF7 in Cancer Immunotherapy SLAMF7, also known as Signaling Lymphocytic Activation Molecule F7, is a surface receptor found on natural killer (NK) cells, T cells,
…
16th Oct 2024
BTLA: A Key Player in Immune Regulation and Cancer Therapy
Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressi
…
16th Oct 2024
LILT: A Novel Immune Checkpoint for Cancer Therapy
Recent advances in immunotherapy have highlighted the importance of targeting immune checkpoints to enhance the immune system’s ability to combat cancer. A new potential target in this gr
…
14th Oct 2024
ICOS: Stimulating the Immune System for Superior Cancer Therapy
Immunotherapy has transformed the landscape of cancer treatment by leveraging the body’s immune system to target and destroy cancer cells. A key player in this process is Inducible T-cell
…
14th Oct 2024
Targeting CD200: Unlocking Immune Suppression in Tumors
Immune evasion is one of the hallmarks of cancer, where tumor cells employ various strategies to suppress immune responses and prevent destruction by the body’s defense systems. CD200, a
…
8th Oct 2024
SIRPα Inhibition: Clearing Tumors by Promoting Phagocytosis
Cancer cells are adept at avoiding destruction by the immune system, often exploiting specific pathways to escape detection and elimination. One of these key mechanisms involves the SIRPα
…
8th Oct 2024
B7-H3: A Promising New Target in Tumor Immunotherapy
B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint molecules that has emerged as a compelling target in tumor immunotherapy. Initially recognized for its role i
…
3rd Oct 2024
TIM-3: Targeting T Cell Exhaustion for Better Immunotherapy Outcomes
T cell immunoglobulin and mucin-domain containing-3 (TIM-3) is an immune checkpoint receptor that plays a pivotal role in T cell exhaustion, a state where T cells lose their ability to ef
…
3rd Oct 2024
GITR: Boosting T Cell Activation for Enhanced Cancer Immunotherapy
Glucocorticoid-induced tumor necrosis factor receptor (GITR) is an immune checkpoint molecule that plays a crucial role in regulating T cell activation and survival. In recent years, GITR
…
3rd Oct 2024
CD25 and Tregs: Understanding the Role of Regulatory T Cells in Tumor Immunity
Regulatory T cells (Tregs) play a crucial role in maintaining immune balance by suppressing excessive immune responses that could lead to tissue damage. However, in the context of cancer,
…
3rd Oct 2024
NK Cells: Unlocking the Potential of Natural Killer Cells in Cancer Therapy
Natural killer (NK) cells are a crucial component of the innate immune system and play a significant role in eliminating tumor cells. Unlike T cells, NK cells can recognize and kill cance
…
3rd Oct 2024